List of Tables
    Table 1. Hypertension Drug CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028
    Table 2. Hypertension Drug Market Trends
    Table 3. Hypertension Drug Market Drivers
    Table 4. Hypertension Drug Market Challenges
    Table 5. Hypertension Drug Market Restraints
    Table 6. Global Hypertension Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Hypertension Drug Sales by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Hypertension Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Hypertension Drug Sales by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Hypertension Drug Manufacturers in Global Market, Ranking by Revenue (2021)
    Table 11. Global Hypertension Drug Revenue by Manufacturer, (US$ Million), 2017-2022
    Table 12. Global Hypertension Drug Revenue Share by Manufacturer, 2017-2022
    Table 13. Global Hypertension Drug Sales by Manufacturer, (K Units), 2017-2022
    Table 14. Global Hypertension Drug Sales Share by Manufacturer, 2017-2022
    Table 15. Global Hypertension Drug Price by Manufacturer (2017-2022) & (USD/Unit)
    Table 16. Global Hypertension Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 17. Global Hypertension Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hypertension Drug as of 2021)
    Table 18. Top Players of Hypertension Drug in Global Market, Headquarters and Distribution of Producing Region
    Table 19. Manufacturers Hypertension Drug Product Type
    Table 20. Date of International Manufacturers Enter into Hypertension Drug Market
    Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 22. Top Hypertension Drug Players in United States Market, Ranking by Revenue (2021)
    Table 23. United States Hypertension Drug Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 24. United States Hypertension Drug Revenue Share by Players, 2020, 2021 & 2022
    Table 25. United States Hypertension Drug Sales by Players, (K Units), 2020, 2021 & 2022
    Table 26. United States Hypertension Drug Sales Share by Players, 2020, 2021 & 2022
    Table 27. Global Hypertension Drug Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 28. Global Hypertension Drug Sales in Volume by Region (2017-2022) & (K Units)
    Table 29. Global Hypertension Drug Sales in Volume Forecast by Region (2023-2028) & (K Units)
    Table 30. Global Hypertension Drug Sales in Value by Region (2017-2022) & (US$ Million)
    Table 31. Global Hypertension Drug Sales in Value Forecast by Region (2023-2028) & (US$ Million)
    Table 32. North America Hypertension Drug Sales in Volume by Country (2017-2028) & (K Units)
    Table 33. North America Hypertension Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 34. Asia Pacific Hypertension Drug Sales in Volume by Region (2017-2028) & (K Units)
    Table 35. Asia Pacific Hypertension Drug Sales in Value by Region (2017-2028) & (US$ Million)
    Table 36. Europe Hypertension Drug Sales in Volume by Country (2017-2028) & (K Units)
    Table 37. Europe Hypertension Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 38. Latin America Hypertension Drug Sales in Volume by Country (2017-2028) & (K Units)
    Table 39. Latin Americaa Hypertension Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 40. Middle East and Africa Hypertension Drug Sales in Volume by Country (2017-2028) & (K Units)
    Table 41. Middle East and Africa Hypertension Drug Sales in Value by Country (2017-2028) & (US$ Million)
    Table 42. Lupin Limited Corporation Information
    Table 43. Lupin Limited Description and Business Overview
    Table 44. Lupin Limited Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 45. Lupin Limited Hypertension Drug Product
    Table 46. Lupin Limited Recent Development
    Table 47. Novartis AG Corporation Information
    Table 48. Novartis AG Description and Business Overview
    Table 49. Novartis AG Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 50. Novartis AG Product
    Table 51. Novartis AG Recent Development
    Table 52. Daiichi - Sankyo Corporation Information
    Table 53. Daiichi - Sankyo Description and Business Overview
    Table 54. Daiichi - Sankyo Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 55. Daiichi - Sankyo Product
    Table 56. Daiichi - Sankyo Recent Development
    Table 57. Pfizer Inc Corporation Information
    Table 58. Pfizer Inc Description and Business Overview
    Table 59. Pfizer Inc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 60. Pfizer Inc Product
    Table 61. Pfizer Inc Recent Development
    Table 62. Ranbaxy Laboratories Limited Corporation Information
    Table 63. Ranbaxy Laboratories Limited Description and Business Overview
    Table 64. Ranbaxy Laboratories Limited Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 65. Ranbaxy Laboratories Limited Product
    Table 66. Ranbaxy Laboratories Limited Recent Development
    Table 67. Sanofi S.A Corporation Information
    Table 68. Sanofi S.A Description and Business Overview
    Table 69. Sanofi S.A Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 70. Sanofi S.A Product
    Table 71. Sanofi S.A Recent Development
    Table 72. AstraZeneca Plc Corporation Information
    Table 73. AstraZeneca Plc Description and Business Overview
    Table 74. AstraZeneca Plc Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 75. AstraZeneca Plc Product
    Table 76. AstraZeneca Plc Recent Development
    Table 77. Johnson & Johnson Ltd Corporation Information
    Table 78. Johnson & Johnson Ltd Description and Business Overview
    Table 79. Johnson & Johnson Ltd Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 80. Johnson & Johnson Ltd Product
    Table 81. Johnson & Johnson Ltd Recent Development
    Table 82. Boehringer Ingelheim Corporation Information
    Table 83. Boehringer Ingelheim Description and Business Overview
    Table 84. Boehringer Ingelheim Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 85. Boehringer Ingelheim Product
    Table 86. Boehringer Ingelheim Recent Development
    Table 87. Merck & Co. Corporation Information
    Table 88. Merck & Co. Description and Business Overview
    Table 89. Merck & Co. Hypertension Drug Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 90. Merck & Co. Product
    Table 91. Merck & Co. Recent Development
    Table 92. Key Raw Materials Lists
    Table 93. Raw Materials Key Suppliers Lists
    Table 94. Hypertension Drug Customers List
    Table 95. Hypertension Drug Distributors List
    Table 96. Research Programs/Design for This Report
    Table 97. Key Data Information from Secondary Sources
    Table 98. Key Data Information from Primary Sources
List of Figures
    Figure 1. Hypertension Drug Product Picture
    Figure 2. Global Hypertension Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Hypertension Drug Market Size 2017-2028 (US$ Million)
    Figure 4. Global Hypertension Drug Sales 2017-2028 (K Units)
    Figure 5. United States Hypertension Drug Revenue, (US$ Million), 2017 VS 2022 VS 2028
    Figure 6. United States Hypertension Drug Market Size 2017-2028 (US$ Million)
    Figure 7. United States Hypertension Drug Sales 2017-2028 (K Units)
    Figure 8. United States Hypertension Drug Market Share in Global, in Value (US$ Million) 2017-2028
    Figure 9. United States Hypertension Drug Market Share in Global, in Volume (K Units) 2017-2028
    Figure 10. Hypertension Drug Report Years Considered
    Figure 11. Product Picture of Calcium Channel Blockers
    Figure 12. Product Picture of Diuretics
    Figure 13. Product Picture of Beta Blockers Vasodilators
    Figure 14. Product Picture of Angiotensin Converting Enzyme Inhibitors
    Figure 15. Product Picture of Alpha Blockers
    Figure 16. Product Picture of Angiotensin Receptor Blockers
    Figure 17. Product Picture of Renin Inhibitors
    Figure 18. Global Hypertension Drug Market Share by Type in 2022 & 2028
    Figure 19. Global Hypertension Drug Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 20. Global Hypertension Drug Sales Market Share in Value by Type (2017-2028)
    Figure 21. Global Hypertension Drug Sales by Type (2017-2028) & (K Units)
    Figure 22. Global Hypertension Drug Sales Market Share in Volume by Type (2017-2028)
    Figure 23. Global Hypertension Drug Price by Type (2017-2028) & (USD/Unit)
    Figure 24. United States Hypertension Drug Market Share by Type in 2022 & 2028
    Figure 25. United States Hypertension Drug Sales in Value by Type (2017-2028) & (US$ Million)
    Figure 26. United States Hypertension Drug Sales Market Share in Value by Type (2017-2028)
    Figure 27. United States Hypertension Drug Sales by Type (2017-2028) & (K Units)
    Figure 28. United States Hypertension Drug Sales Market Share in Volume by Type (2017-2028)
    Figure 29. United States Hypertension Drug Price by Type (2017-2028) & (USD/Unit)
    Figure 30. Product Picture of Hospital
    Figure 31. Product Picture of Private Clinic
    Figure 32. Product Picture of Others
    Figure 33. Global Hypertension Drug Market Share by Application in 2022 & 2028
    Figure 34. Global Hypertension Drug Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 35. Global Hypertension Drug Sales Market Share in Value by Application (2017-2028)
    Figure 36. Global Hypertension Drug Sales by Application (2017-2028) & (K Units)
    Figure 37. Global Hypertension Drug Sales Market Share in Volume by Application (2017-2028)
    Figure 38. Global Hypertension Drug Price by Application (2017-2028) & (USD/Unit)
    Figure 39. United States Hypertension Drug Market Share by Application in 2022 & 2028
    Figure 40. United States Hypertension Drug Sales in Value by Application (2017-2028) & (US$ Million)
    Figure 41. United States Hypertension Drug Sales Market Share in Value by Application (2017-2028)
    Figure 42. United States Hypertension Drug Sales by Application (2017-2028) & (K Units)
    Figure 43. United States Hypertension Drug Sales Market Share in Volume by Application (2017-2028)
    Figure 44. United States Hypertension Drug Price by Application (2017-2028) & (USD/Unit)
    Figure 45. North America Hypertension Drug Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 46. North America Hypertension Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 47. U.S. Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Canada Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Europe Hypertension Drug Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 50. Europe Hypertension Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 51. Germany Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 52. France Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 53. U.K. Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Italy Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 55. Russia Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Asia-Pacific Hypertension Drug Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 57. Asia-Pacific Hypertension Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 58. China Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 59. Japan Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 60. South Korea Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 61. India Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 62. Australia Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 63. Taiwan Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 64. Indonesia Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 65. Thailand Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 66. Malaysia Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 67. Philippines Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 68. Latin America Hypertension Drug Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 69. Latin America Hypertension Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 70. Mexico Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 71. Brazil Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 72. Argentina Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 73. Middle East & Africa Hypertension Drug Sales in Volume Growth Rate 2017-2028 (K Units)
    Figure 74. Middle East & Africa Hypertension Drug Sales in Value Growth Rate 2017-2028 (US$ Million)
    Figure 75. Turkey Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 76. Saudi Arabia Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 77. U.A.E Hypertension Drug Sales in Value Growth Rate (2017-2028) & (US$ Million)
    Figure 78. Hypertension Drug Value Chain
    Figure 79. Hypertension Drug Production Process
    Figure 80. Channels of Distribution
    Figure 81. Distributors Profiles
    Figure 82. Bottom-up and Top-down Approaches for This Report
    Figure 83. Data Triangulation
    Figure 84. Key Executives Interviewed